Discovery of the Inhibitory Effect of a Phosphatidylinositol Derivative on P-Glycoprotein by Virtual Screening Followed by In Vitro Cellular Studies

P-glycoprotein is capable of effluxing a broad range of cytosolic and membrane penetrating xenobiotic substrates, thus leading to multi-drug resistance and posing a threat for the therapeutic treatment of several diseases, including cancer and central nervous disorders. Herein, a virtual screening campaign followed by experimental validation in Caco-2, MDKCII, and MDKCII mdr1 transfected cell lines has been conducted for the identification of novel phospholipids with P-gp transportation inhibitory activity. Phosphatidylinositol-(1,2-dioctanoyl)-sodium salt (8∶0 PI) was found to significantly inhibit transmembrane P-gp transportation in vitro in a reproducible-, cell line-, and substrate-independent manner. Further tests are needed to determine whether this and other phosphatidylinositols could be co-administered with oral drugs to successfully increase their bioavailability. Moreover, as phosphatidylinositols and phosphoinositides are present in the human diet and are known to play an important role in signal transduction and cell motility, our finding could be of substantial interest for nutrition science as well.

[1]  K. Moitra,et al.  Allosteric Modulation Bypasses the Requirement for ATP Hydrolysis in Regenerating Low Affinity Transition State Conformation of Human P-glycoprotein* , 2006, Journal of Biological Chemistry.

[2]  F. Sharom.  Shedding light on drug transport: structure and function of the P-glycoprotein multidrug transporter (ABCB1). , 2006, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[3]  R. Schubert,et al.  Inhibitory effect of phospholipids on P-glycoprotein: cellular studies in Caco-2, MDCKII mdr1 and MDCKII wildtype cells and P-gp ATPase activity measurements. , 2012, Biochimica et biophysica acta.

[4]  Gerhard F. Ecker,et al.  Exhaustive Sampling of Docking Poses Reveals Binding Hypotheses for Propafenone Type Inhibitors of P-Glycoprotein , 2011, PLoS Comput. Biol..

[5]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[6]  N. Oku,et al.  Anti-obesity effect of phosphatidylinositol on diet-induced obesity in mice. , 2010, Journal of agricultural and food chemistry.

[7]  Yue Weng,et al.  Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding , 2009, Science.

[8]  A. Kabanov,et al.  Effect of Pluronic P85 on ATPase Activity of Drug Efflux Transporters , 2004, Pharmaceutical Research.

[9]  G. Meer,et al.  Membrane lipids: where they are and how they behave , 2008, Nature Reviews Molecular Cell Biology.

[10]  L. Mir,et al.  Effects of steroids and verapamil on P-glycoprotein ATPase activity: progesterone, desoxycorticosterone, corticosterone and verapamil are mutually non-exclusive modulators. , 1996, The Biochemical journal.

[11]  Bo Feng,et al.  In Vitro P-glycoprotein Assays to Predict the in Vivo Interactions of P-glycoprotein with Drugs in the Central Nervous System , 2008, Drug Metabolism and Disposition.

[12]  Seyun Kim,et al.  Annals of the New York Academy of Sciences Inositol Polyphosphate Multikinase Signaling in the Regulation of Metabolism , 2022 .

[13]  V. Andersen,et al.  Human intestinal P‐glycoprotein activity estimated by the model substrate digoxin , 2007, Scandinavian journal of clinical and laboratory investigation.

[14]  C. Inagaki,et al.  Soybean-derived phosphatidylinositol inhibits in vivo low concentrations of amyloid beta protein-induced degeneration of hippocampal neurons in V337M human tau-expressing mice. , 2007, Life sciences.

[15]  Daniel J. Blankenberg,et al.  Galaxy: a platform for interactive large-scale genome analysis. , 2005, Genome research.

[16]  A. Schinkel,et al.  Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. , 2003, Advanced drug delivery reviews.

[17]  Caroline A. Lee,et al.  P-glycoprotein related drug interactions: clinical importance and a consideration of disease states , 2010, Expert opinion on drug metabolism & toxicology.

[18]  Lutz Schmitt,et al.  Multidrug efflux pumps: Substrate selection in ATP‐binding cassette multidrug efflux pumps – first come, first served? , 2010, The FEBS journal.

[19]  L. Walker,et al.  The role of the ATP-binding cassette transporter P-glycoprotein in the transport of β-amyloid across the blood-brain barrier. , 2011, Current pharmaceutical design.

[20]  A. Seelig,et al.  P-glycoprotein-ATPase modulation: the molecular mechanisms. , 2012, Biophysical journal.

[21]  F. Sharom,et al.  The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter. , 1999, Biochemistry.

[22]  Thomas J. Raub,et al.  Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. , 1989, Gastroenterology.

[23]  Torsten Schwede,et al.  BIOINFORMATICS Bioinformatics Advance Access published November 12, 2005 The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling , 2022 .

[24]  M. R. Lugo,et al.  Interaction of LDS-751 and rhodamine 123 with P-glycoprotein: evidence for simultaneous binding of both drugs. , 2005, Biochemistry.

[25]  B. Sikic,et al.  Molecular Pathways: Regulation and Therapeutic Implications of Multidrug Resistance , 2012, Clinical Cancer Research.

[26]  A. Palmeira,et al.  Three decades of P-gp inhibitors: skimming through several generations and scaffolds. , 2012, Current medicinal chemistry.

[27]  G. Amidon,et al.  Human Jejunal Permeability of Cyclosporin A: Influence of Surfactants on P-Glycoprotein Efflux in Caco-2 Cells , 2003, Pharmaceutical Research.

[28]  C. Higgins,et al.  Multiple molecular mechanisms for multidrug resistance transporters , 2007, Nature.

[29]  James E Polli,et al.  Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[30]  J. Burgess,et al.  Phosphatidylinositol increases HDL-C levels in humans Published, JLR Papers in Press, December 1, 2004. DOI 10.1194/jlr.M400438-JLR200 , 2005, Journal of Lipid Research.

[31]  S. Moss.  How Actin Gets the PIP , 2012, Science Signaling.

[32]  John Buckingham,et al.  Dictionary of natural products , 2014 .

[33]  H. Hara,et al.  Phosphatidylinositol inhibits vascular endothelial growth factor-A--induced migration of human umbilical vein endothelial cells. , 2008, Journal of pharmacological sciences.

[34]  Y. Berger,et al.  The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications , 1995, Cell Biology and Toxicology.

[35]  D. Fan,et al.  New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives. , 2010, Future oncology.

[36]  S. Bates,et al.  Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[37]  D. Murray,et al.  Plasma membrane phosphoinositide organization by protein electrostatics , 2005, Nature.

[38]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[39]  M. Wallace.  Effects of Alzheimer's disease-related beta amyloid protein fragments on enzymes metabolizing phosphoinositides in brain. , 1994, Biochimica et biophysica acta.

[40]  Claus-Michael Lehr,et al.  Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access. , 2010, Molecular pharmaceutics.

[41]  A. Wilde,et al.  Phosphoinositide Function in Cytokinesis , 2011, Current Biology.

[42]  O. Levran,et al.  Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment , 2010, Annals of the New York Academy of Sciences.